Who would benefit from average value‐based pricing?

There has been debate over the appropriate basis by which decisions relating to the adoption of health technologies should be made in the presence of heterogeneity in outcomes across patients. Stratified cost-effectiveness analysis (SCEA) was originally proposed as a method of determining the optimal patient subgroups or strata for which treatments should be reimbursed (Coyle, Buxton, & O'Brien, 2003). SCEA is based on the recognition that, in...